11/20
08:00 am
evax
Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1
Low
Report
Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1
11/12
08:00 am
evax
Evaxion announce 2026 financial calendar
Low
Report
Evaxion announce 2026 financial calendar
11/7
05:21 pm
evax
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 [Yahoo! Finance]
Low
Report
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 [Yahoo! Finance]
11/7
05:10 pm
evax
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
Low
Report
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
11/6
07:30 am
evax
Evaxion announces business update and third quarter 2025 financial results
High
Report
Evaxion announces business update and third quarter 2025 financial results
11/3
09:00 am
evax
Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate
Medium
Report
Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate
11/1
06:55 am
evax
Evaxion A/S (NASDAQ:EVAX) was upgraded by analysts at Jones Trading to a "strong-buy" rating.
Low
Report
Evaxion A/S (NASDAQ:EVAX) was upgraded by analysts at Jones Trading to a "strong-buy" rating.
10/31
09:05 am
evax
Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
Low
Report
Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
10/31
08:00 am
evax
Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
Low
Report
Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
10/30
09:04 am
evax
Evaxion A/S (NASDAQ:EVAX) is now covered by analysts at Edward Jones. They set a "buy" rating and a $10.00 price target on the stock.
Low
Report
Evaxion A/S (NASDAQ:EVAX) is now covered by analysts at Edward Jones. They set a "buy" rating and a $10.00 price target on the stock.
10/30
08:00 am
evax
Evaxion raises $7.2 million, extending cash runway to second half of 2027
Low
Report
Evaxion raises $7.2 million, extending cash runway to second half of 2027
10/27
08:00 am
evax
Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer
Medium
Report
Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer
10/26
06:18 am
evax
Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data [Yahoo! Finance]
Medium
Report
Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data [Yahoo! Finance]
10/20
09:23 am
evax
Evaxion A/S (NASDAQ:EVAX) had its price target raised by analysts at Lake Street Capital from $6.00 to $11.00. They now have a "buy" rating on the stock.
Low
Report
Evaxion A/S (NASDAQ:EVAX) had its price target raised by analysts at Lake Street Capital from $6.00 to $11.00. They now have a "buy" rating on the stock.
10/20
08:08 am
evax
Evaxion A/S (NASDAQ:EVAX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Evaxion A/S (NASDAQ:EVAX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
10/17
08:15 am
evax
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
High
Report
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
10/14
12:13 pm
evax
Evaxion A/S (NASDAQ:EVAX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Evaxion A/S (NASDAQ:EVAX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/13
08:00 am
evax
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
Low
Report
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
10/8
08:40 am
evax
Evaxion expands AI-Immunology™ platform with automated vaccine design module [Yahoo! Finance]
Medium
Report
Evaxion expands AI-Immunology™ platform with automated vaccine design module [Yahoo! Finance]
10/8
08:12 am
evax
Evaxion expands AI-Immunology™ platform with automated vaccine design module
Medium
Report
Evaxion expands AI-Immunology™ platform with automated vaccine design module
10/3
03:35 pm
evax
Evaxion A/S (NASDAQ:EVAX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Evaxion A/S (NASDAQ:EVAX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/3
09:45 am
evax
Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting [Yahoo! Finance]
High
Report
Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting [Yahoo! Finance]
10/3
09:00 am
evax
Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting
High
Report
Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting
9/25
11:52 am
evax
Evaxion A/S (NASDAQ:EVAX) had its price target raised by analysts at HC Wainwright from $14.00 to $16.00. They now have a "buy" rating on the stock.
High
Report
Evaxion A/S (NASDAQ:EVAX) had its price target raised by analysts at HC Wainwright from $14.00 to $16.00. They now have a "buy" rating on the stock.
9/25
08:10 am
evax
Evaxion out-licenses vaccine candidate EVX-B3 to MSD [Yahoo! Finance]
Medium
Report
Evaxion out-licenses vaccine candidate EVX-B3 to MSD [Yahoo! Finance]